Clinical and radiological characteristics and outcomes of patients with recurrent or relapsing tumefactive demyelination

Abstract

Background: Relapsing or recurrent tumefactive demyelination is rare and has not been studied beyond individual case reports. Objective: We examined the clinical course, neuroimaging, cerebrospinal fluid (CSF), treatment and outcomes of patients with recurrent tumefactive demyelinating lesions (TDLs). Methods: We used PubMed to identify reports of recurrent TDLs and included the details of an additional, unpublished patient. Results: We identified 18 cases (11F, 7 M). The median age at onset of the index TDL was 37 years (range 12?72) and most were solitary lesions 72 % (13/18). CSF-restricted oligoclonal bands (OCBs) were detected in 25 % (4/16). Only one of those tested (n = 13) was positive for AQP4-IgG. A moderate-to-marked treatment response (high dose corticosteroid with or without additional plasmapheresis, IVIg or disease modifying therapies) was evident in 89 % of treated patients. Median EDSS at the median follow-up of 36 months (range 6?144) was 2 (range 1?10). Most remained ambulatory (EDSS < 4 in 13/18), but 1 patient died. Conclusion: The median age of patients with relapsing TDLs is similar to that of typical MS, but differences include a lower female:male sex ratio, larger lesions, and a comparative lack of CSF-restricted OCBs. Outcomes vary among this group of patients ranging from minimal disability through to death. � 2023